Innoviva Specialty Therapeutics Earns Strong Performance Rating in Access to Medicine Foundation's 2026 Antimicrobial Resistance Benchmark ReportBusiness Wire • 03/10/26
Innoviva, Inc. (INVA) Presents at Oppenheimer 36th Annual Healthcare Life Sciences Conference TranscriptSeeking Alpha • 02/27/26
Innoviva Reports Fourth Quarter and Full Year 2025 Financial Results; Highlights Recent Company ProgressBusiness Wire • 02/25/26
Innoviva to Participate in the Oppenheimer 36th Annual Healthcare Life Sciences ConferenceBusiness Wire • 02/19/26
U.S. FDA Approves NUZOLVENCE® (zoliflodacin), a First-in-Class, Single-dose, Oral Antibiotic for the Treatment of Uncomplicated Urogenital Gonorrhea in Adults and AdolescentsBusiness Wire • 12/12/25
US FDA approves Innoviva's oral antibiotic for common sexually transmitted infectionsReuters • 12/12/25
Innoviva Specialty Therapeutics Announces Publication in The Lancet of Positive Zoliflodacin Phase 3 Data for the Treatment of Uncomplicated Urogenital GonorrheaBusiness Wire • 12/11/25
Innoviva to Participate in the 37th Annual Piper Sandler Healthcare ConferenceBusiness Wire • 11/25/25
Innoviva Reports Third Quarter 2025 Financial Results; Highlights Recent Company ProgressBusiness Wire • 11/05/25
Strength Seen in Innoviva (INVA): Can Its 5.5% Jump Turn into More Strength?Zacks Investment Research • 10/23/25
Innoviva Specialty Therapeutics Announces Oral Presentation Featuring New Analyses from the Zoliflodacin Pivotal Phase 3 Trial at IDWeek 2025Business Wire • 10/20/25
Innoviva Specialty Therapeutics to Deliver Six Presentations from its Infectious Diseases and Critical Care Portfolio at IDWeek 2025Business Wire • 10/07/25
Innoviva, Inc. (INVA) Presents At Citi's Biopharma Back To School Conference TranscriptSeeking Alpha • 09/02/25
Innoviva Specialty Therapeutics' Antimicrobial Therapies ZEVTERA® and XACDURO® Nominated for the 2025 Prix Galien USA Best Pharmaceutical Product AwardBusiness Wire • 08/13/25
Innoviva Reports Second Quarter 2025 Financial Results; Highlights Recent Company ProgressBusiness Wire • 08/06/25
FDA Grants Priority Review for Zoliflodacin New Drug Application for the Treatment of Uncomplicated Gonorrhea and Assigns Target PDUFA Date of December 15, 2025Business Wire • 06/12/25
Innoviva Specialty Therapeutics Receives FDA New Drug Application Acceptance for Zoliflodacin, a First-in-Class Oral Antibiotic for Uncomplicated Gonorrhea in AdultsBusiness Wire • 06/10/25
ZEVTERA® (ceftobiprole), an Advanced-Generation Cephalosporin Antibiotic Now Commercially Available in the U.S. to Treat Three Types of Bacterial InfectionsBusiness Wire • 05/20/25